@article{27c8d41f948246d4b9b31c6ed8bc16de,
title = "Could repetitive transcranial magnetic stimulation improve neurocognition in early-onset schizophrenia spectrum disorders?",
author = "Croarkin, {Paul E.} and Daskalakis, {Zafiris J.}",
note = "Funding Information: Disclosure: Dr. Croarkin has received research grant support from the Stanley Medical Research Institute , the National Alliance for Research on Schizophrenia and Depression (NARSAD) Brain and Behavior Research Foundation Award , and Pfizer Inc . He has served as a site sub- or principal investigator (without additional compensation) for Eli Lilly and Co., Forest Laboratories Inc., Merck and Co. Inc., and Pfizer Inc. Dr. Daskalakis has received external funding from Neuronetics Inc., Brainsway Ltd., and Aspect Medical Systems Inc. He has received travel allowances from Pfizer Inc. and Merck and Co. Inc. He has received speaker honoraria through Sepracor Inc. (now Sunovion Pharmaceuticals Inc.), and has served on the advisory board of F. Hoffmann-La Roche Ltd. He has received funding and support from the Ontario Mental Health Foundation, the Canadian Institutes of Health Research, the Grant Family through the Centre for Addiction and Mental Health Foundation , and the NARSAD Brain and Behavior Research Foundation Award . ",
year = "2012",
month = sep,
doi = "10.1016/j.jaac.2012.05.012",
language = "English (US)",
volume = "51",
pages = "949--951",
journal = "Journal of the American Academy of Child and Adolescent Psychiatry",
issn = "0890-8567",
publisher = "Elsevier Limited",
number = "9",
}